about
Connexin40 imparts conduction heterogeneity to atrial tissueIncreased plasma catalytic iron in patients may mediate acute kidney injury and death following cardiac surgeryInterpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia.Implementation of a CKD checklist for primary care providersPlasma catalytic iron, AKI, and death among critically ill patientsCathelicidin antimicrobial protein, vitamin D, and risk of death in critically ill patients.The usefulness of diagnostic testing in the initial evaluation of chronic kidney disease.Excessive diagnostic testing in acute kidney injuryFGF-23 levels in patients with AKI and risk of adverse outcomes.Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.Intraoperative High-Dose Dexamethasone and Severe AKI after Cardiac SurgeryFibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgeryColpocephaly in adultsDysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes.Clinical predictors of diagnostic testing utility in the initial evaluation of chronic kidney diseasePlasma FGF23 levels increase rapidly after acute kidney injury.An electronic alert to decrease Kayexalate ordering.SOMOSAT: Utility of a web-based self-assessment tool in undergraduate medical education.Glomerular disease: why is there a dearth of high quality clinical trials?Impact of nonphysician staffing on outcomes in a medical ICU.Laxative abuse, eating disorders, and kidney stones: a case report and review of the literature.Catalytic iron and acute kidney injury.C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients.BPI Fold-Containing Family A Member 2/Parotid Secretory Protein Is an Early Biomarker of AKI.Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness.Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsPatient visibility and ICU mortality: a conceptual replication.Chloride-liberal fluids and intracellular acidosis.Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness.Acute blood loss stimulates fibroblast growth factor 23 production.End Points for Clinical Trials in Acute Kidney Injury.Relationship between ICU design and mortality.Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell TransplantationElevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injuryFibroblast Growth Factor 23 Associates with Death in Critically Ill PatientsRisk Prediction Models for Acute Kidney Injury in Critically Ill Patients: Opus in ProgressuA case of severe hypothyroidism due to lenalidomideIron Chelation as a Potential Therapeutic Strategy for AKI PreventionIntroduction: Cross-Talk Between the Kidneys and Remote Organ Systems in AKIDysregulated Mineral Metabolism in AKI
P50
Q28508423-D349B9E4-8A4A-4990-9D76-C677FC8B49B8Q28817921-53169D11-4060-4B82-9EB5-877D2E05AADEQ33371531-288C7ACF-85C1-4B40-B49D-9E80D8380935Q34124728-8A05E57A-3EFC-47B2-ACDA-C31DA1D4F10FQ34455171-1D7A1FAE-0765-4AB2-ABFF-4FF047837576Q35170224-7A34F86F-9205-498F-A2B6-ECBD20AEB78CQ35572227-C9F77BDB-CA4A-4506-AEFF-DEE0CD0D1799Q35895668-95BCAF92-0A4D-4051-BE92-1DAAB1FFBA6EQ36126891-08ADA730-3967-4719-B328-3B954F117B02Q36265388-C5F3F56B-75ED-4A15-92E3-FC1586A32FF5Q36314938-A9F23549-9C27-480A-862F-7A5D6BD39356Q36711992-E4E55EFF-E5D3-410E-9BA0-46A853AAEE7EQ36894321-CBAC35D4-73E9-4B46-AF2B-E4A9A466AF1BQ36941143-C1D0DD5A-67AC-4248-BE73-F472846EFE60Q37143583-C7CB1D6B-580B-4483-9847-6DCAFDBF945FQ37154351-B1A6927E-B975-423E-A221-71BF50FA7919Q37420987-1528B161-8B4C-40BB-86E2-EE6B967E5B44Q37610329-6096B5E8-6ED5-4E2C-A4E9-A602F2CCFF05Q37762438-69531ABC-01BB-4505-8191-664BF7F6E698Q37851760-D4D33C04-6D0C-4E66-BD33-5D3182712C82Q38007728-65515F2D-C789-4BA8-9417-4A9DA8452B8BQ38801048-94133887-6377-47E2-BC4C-A405EB973493Q40095461-751E215D-E183-408B-AA86-1C0F0462F39BQ40107425-F59C01B0-9C8C-45AC-B396-D3CD1F806186Q40405562-F0B66B02-F080-49CD-867B-37B9DC6B708DQ41831841-E357CABF-1262-422D-A2E9-6781C5234BC1Q44423443-A9778593-4AB6-4792-8C36-3D7244D5AA36Q44760933-ABEB4CD2-FCD4-4779-B856-1F9F5BE51E51Q48488655-293A14C8-534F-486E-A596-D3DDC5A2D43CQ50197535-387E0803-5E47-4F87-BEDD-592A0DF17465Q50350882-7CCF4A56-604C-4FD8-A8E4-8F1389D96D57Q51788927-1C96D082-62B4-4F07-9F67-D9A705AEE977Q58415027-2B46FAE5-7459-457D-9962-C96C330FB460Q82347840-2D04313A-FDE1-487E-A157-0064354432F9Q88007698-AB575DC3-76E6-46E0-A5FA-A7D0D889BEE7Q88935010-D6941199-0E4E-4ECA-B187-C1965B590E2BQ90170847-4E1A27D3-74C8-414A-9A60-E3B03D4A398EQ90286774-A5CF460C-87CB-4D58-BFA9-6ED87F64D1E4Q90868474-424D7DCB-4A8D-41FB-88F9-4716CAFAA08DQ90868500-50178E50-4E3F-4260-AC6D-4601B7D033FE
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
David E Leaf
@ast
David E Leaf
@en
David E Leaf
@es
David E Leaf
@nl
type
label
David E Leaf
@ast
David E Leaf
@en
David E Leaf
@es
David E Leaf
@nl
prefLabel
David E Leaf
@ast
David E Leaf
@en
David E Leaf
@es
David E Leaf
@nl
P1153
16202977400
P21
P31
P496
0000-0001-7875-090X